Emergent BioSolutions Inc expected to post a loss of 49 cents a share - Earnings Preview

Emergent BioSolutions

04/08/2025 23:31

Emergent BioSolutions Inc EBS.N, EBS is expected to  show a fall in quarterly revenue when it reports  results on August 6 for the period ending June 30 2025

The Gaithersburg Maryland-based  company is expected to report a 42.5% decrease in revenue to $146.367 million from $254.7 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on May 7 2025, for the period ended June 30, was for revenue between $95.00 million and $120.00 million. (Sales/Revenue majority basis is on Total Revenue.)

​LSEG's mean analyst estimate for Emergent BioSolutions Inc is for a loss of 49 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 55.9% above its last closing price of $5.95

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
0.46
0.44
0.71
Beat
61.4
Dec. 31 2025
-0.50
-0.49
0.05
Beat
110.1
Sep. 30 2024
0.13
0.14
1.37
Beat
878.6​
Jun. 30 2024
-0.94
-0.94
-2.32
Missed
-145.5
​​Mar. 31 2024
-0.87
-0.86
0.59
Beat
168.6
Dec. 31 2023
-0.14
-0.19
-0.77
Missed
-305.3​
Sep. 30 2023
-0.25
-0.22
-0.48
Missed
-114.9
Jun. 30 2023
-0.53
-0.49
-1.06
Missed
-117.8

This summary was machine generated August 4 at 22:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)